# Drug Allergy Assessment and Penicillin Allergy De-labeling

## Introduction

Approximately **10-15% of hospitalized patients** report a drug allergy, with penicillin being the most commonly reported. However, over **90% of patients labeled as penicillin-allergic** are not truly allergic when formally tested. Inappropriate allergy labels lead to the use of broader-spectrum, more expensive, and often less effective antibiotics, driving antimicrobial resistance and increasing adverse events.

## Drug Allergy Classification

### Immune-Mediated Reactions (Gell and Coombs)

| Type | Mechanism | Timing | Examples |
|------|-----------|--------|----------|
| I | IgE-mediated (immediate) | Minutes to 6 hours | Urticaria, angioedema, anaphylaxis |
| II | Cytotoxic (IgG/IgM) | Days | Drug-induced hemolytic anemia, cytopenias |
| III | Immune complex | 1-3 weeks | Serum sickness, drug-induced vasculitis |
| IV | Delayed T-cell-mediated | 24 hours to weeks | Maculopapular rash, SJS/TEN, DRESS, AGEP |

- **Type I (Immediate/IgE-mediated)**: urticaria, angioedema, bronchospasm, anaphylaxis; occurs within 1-6 hours
- **Type II (Cytotoxic)**: drug-induced cytopenias (e.g., hemolytic anemia from cephalosporins)
- **Type III (Immune complex)**: serum sickness, drug-induced vasculitis; occurs 1-3 weeks after exposure
- **Type IV (Delayed/T-cell-mediated)**: maculopapular rash, contact dermatitis, SJS/TEN, DRESS; occurs 24 hours to weeks later

### Non-Immune Reactions

- **Drug intolerance**: GI upset, headache (not a true allergy)
- **Drug side effects**: predictable pharmacologic effects (e.g., diarrhea with amoxicillin)
- **Non-allergic drug hypersensitivity**: vancomycin-associated Red Man Syndrome (histamine-mediated, not IgE)

## Taking a Thorough Drug Allergy History

- **What was the reaction?** Specific symptoms (rash, swelling, breathing difficulty, GI upset)
- **When did it occur?** Timing relative to drug administration
- **How long ago?** IgE-mediated sensitivity wanes over time (80% lose sensitivity within 10 years)
- **Was treatment required?** Epinephrine, hospitalization, ICU admission
- **Has the drug been tolerated since?** If tolerated subsequently, allergy is effectively ruled out
- **What was the indication?** Viral illness with rash may have been misattributed

![Drug allergy history assessment framework](images/drug-allergy-history.png)

## Penicillin Allergy: The Scope of the Problem

- Penicillin allergy is documented in **10% of the US population**
- Patients with penicillin allergy labels receive more **vancomycin, fluoroquinolones, and carbapenems**
- This leads to increased rates of **C. difficile infection, MRSA, VRE**, and antimicrobial resistance
- Penicillin allergy labels are associated with **longer hospital stays**, higher costs, and worse surgical site infection rates
- **Cross-reactivity** between penicillins and cephalosporins is approximately **1-2%** (much lower than historically cited 10%)

## Penicillin Allergy De-labeling Strategies

### Risk Stratification

| Risk Level | History | Approach |
|-----------|---------|----------|
| Low | Remote childhood rash, GI symptoms only, unknown reaction >10 years, family history | Direct oral amoxicillin challenge |
| Moderate | Urticaria or pruritic rash within hours | Skin testing → graded challenge if negative |
| High | Anaphylaxis, angioedema, bronchospasm, SJS/TEN, DRESS | Permanent avoidance (SJS/TEN/DRESS); allergist referral (anaphylaxis) |

- **Low risk**: remote childhood rash, isolated GI symptoms, family history only, unknown reaction > 10 years ago
- **Moderate risk**: urticaria, pruritic rash occurring within hours of administration
- **High risk**: anaphylaxis, angioedema, bronchospasm, or severe cutaneous reactions (SJS/TEN, DRESS, AGEP)

### Testing and Challenge Approaches

- **Direct oral challenge (amoxicillin)**: appropriate for low-risk patients; give supervised dose and observe for 1-2 hours
- **Penicillin skin testing**: uses major determinant (penicilloyl-polylysine/Pre-Pen) and minor determinants; 97-99% negative predictive value
- **Graded dose challenge**: for moderate-risk patients after negative skin testing
- Patients with history of **SJS/TEN, DRESS, or AGEP** should **never** be re-challenged with the offending drug

### Implementation in Clinical Practice

- **Antibiotic stewardship programs** should integrate penicillin allergy assessment
- **Pharmacist-led** and **nurse-driven** protocols for allergy interviews and low-risk direct challenges are effective
- Electronic health record alerts can identify candidates for de-labeling
- After successful challenge, **update the allergy record** and educate the patient

![Penicillin allergy de-labeling pathway](images/penicillin-delabeling-pathway.png)

## Cross-Reactivity Between Beta-Lactams

- Penicillin-cephalosporin cross-reactivity is **1-2%**, primarily driven by similar R1 side chains
- **Cephalosporins with dissimilar side chains** (e.g., ceftriaxone, cefepime) have negligible cross-reactivity with amoxicillin/ampicillin
- **Carbapenems** have < 1% cross-reactivity with penicillins and can generally be administered safely
- **Aztreonam** has no cross-reactivity with penicillins (except with ceftazidime, which shares an identical side chain)

## Severe Drug Reactions Requiring Permanent Avoidance

- **Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)**: life-threatening desquamation; avoid the drug class permanently
- **Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)**: multi-organ involvement; 10% mortality
- **Acute Generalized Exanthematous Pustulosis (AGEP)**: widespread sterile pustules
- **Drug-induced anaphylaxis with confirmed testing**: maintain allergy label with clear documentation

![Severe cutaneous adverse drug reaction recognition guide](images/severe-drug-reactions.png)

## Key Clinical Pearls

- Over 90% of patients labeled penicillin-allergic can safely receive penicillins after formal evaluation.
- A detailed allergy history is the most important first step and can often risk-stratify without skin testing.
- Low-risk patients can undergo direct oral amoxicillin challenge without prior skin testing.
- True penicillin-cephalosporin cross-reactivity is approximately 1-2%, not the historical 10%.
- Never re-challenge patients with a history of SJS/TEN, DRESS, or AGEP to the implicated drug.

## References

1. Shenoy ES, Macy E, Rowe T, et al. Evaluation and Management of Penicillin Allergy: A Review. *JAMA*. 2019;321(2):188-199.
2. Blumenthal KG, Peter JG, Trubiano JA, et al. Antibiotic Allergy. *The Lancet*. 2019;393(10167):183-198.
3. Macy E, Contreras R. Health Care Use and Serious Infection Prevalence Associated with Penicillin "Allergy" in Hospitalized Patients. *Journal of Allergy and Clinical Immunology*. 2014;133(3):790-796.
4. Joint Task Force on Practice Parameters. Drug Allergy: An Updated Practice Parameter. *Annals of Allergy, Asthma & Immunology*. 2010;105(4):259-273.